Progress in mucosal immunization for protection against pneumococcal pneumonia

References

• Ramos-Sevillano E, Ercoli G, Brown JS. Mechanisms of naturally acquired immunity to Streptococcus pneumoniae. Front Immunol. 2019;10:358. DOI: 10.3389/fimmu.2019.00358. eCollection 2019. Review. PubMed PMID: 30881363; PubMed Central PMCID: PMC6405633.
   PubMed Web of Science ®Google Scholar
• Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3(7):a010215.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788.
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Käyhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–855.
   PubMed Web of Science ®Google Scholar
• Van Buynder P, Booy R. Pneumococcal vaccination in older persons: where are we today? Pneumonia. 2018;10:1.
   Web of Science ®Google Scholar
• Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–899.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408–1416.
   PubMed Web of Science ®Google Scholar
• Papadatou I, Tzovara I, Licciardi PV. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. Vaccines (Basel). 2019;7(1):E13.
   PubMed Web of Science ®Google Scholar
• WHO. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – february 2019. Weekly Epidemiological Rec. 2019;94(8):85–104.
   Google Scholar
• Luna CM, Pulido L, Burgos D. Why is the rate of pneumococcal pneumonia declining? Curr Opin Pulm Med. 2018;24(3):205–211.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45(6):1632–1641.
   PubMed Web of Science ®Google Scholar
• Fortunato F, Martinelli D, Cappelli MG, et al. Impact of pneumococcal conjugate universal routine vaccination on pneumococcal disease in Italian children. J Immunol Res. 2015;2015:206757.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543.
   PubMed Web of Science ®Google Scholar
• Corcoran M, Vickers I, Mereckiene J, et al. The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect? Epidemiol Infect. 2017;145(11):2390–2399.
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017;5(8):648–656.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Krizova P, Valentiner-Branth P on behalf of The SpIDnet/I-MOVE+ Pneumo Group, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74:473–482.
   PubMed Web of Science ®Google Scholar
• Mitsi E, Roche AM, Reiné J, et al. Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage. Mucosal Immunol. 2017;10:385–394.
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, et al. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013;32:133–145.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community‐randomized trial. J Infect Dis. 2007;196:1211–1220.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon‐Lavi N, Fraser D, et al. Serum serotype‐specific pneumococcal anticapsular immunoglobulin G Concentrations after immunization with a 9‐valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367–376.
   PubMed Web of Science ®Google Scholar
• German EL, Solórzano C, Sunny S, et al. Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density. Vaccine. 2019. doi:10.1016/J.VACCINE.2019.05.080.
   PubMed Web of Science ®Google Scholar
• Dunne EM, Satzke C, Ratu FT, et al. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys. Lancet Glob Heal. 2018;6:e1375–e1385.
   PubMed Web of Science ®Google Scholar
• Hanage WP, Finkelstein JA, Huang SS, et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics. 2010;2:80–84.
   PubMed Web of Science ®Google Scholar
• Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361:2189–2195.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–768.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–451.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Richter L, Schmid D, Kanitz EE, et al. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS One. 2019;14:e0210081.
   PubMed Web of Science ®Google Scholar
• Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018;36:7744–7752.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Etyang AO, Morpeth SC, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019;393:2146–2154.
   PubMed Web of Science ®Google Scholar
• Sime WT, Aseffa A, Woldeamanuel Y, et al. Serotype and molecular diversity of nasopharyngeal Streptococcus pneumoniae isolates from children before and after vaccination with the ten-valent pneumococcal conjugate vaccine (PCV10) in Ethiopia. BMC Infect Dis. 2019;19:409.
   PubMed Web of Science ®Google Scholar
• Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15(3):549–559.
   PubMed Web of Science ®Google Scholar
• Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539.
   PubMed Web of Science ®Google Scholar
• Peterson JT, Stacey HL, MacNair JE, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548.
   PubMed Web of Science ®Google Scholar
• Hulten KG. The changing epidemiology of pneumococcal diseases. Lancet Infect Dis. 2018;18(9):929–930.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines. 2017;16(12):1181–1190.
   PubMed Web of Science ®Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, et al. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants. Vaccine. 2017;35(35Pt B):4603–4611.
   PubMed Web of Science ®Google Scholar
• Campo JJ, Le TQ, Pablo JV, et al. Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. Elife. 2018;7:e37015.
   PubMed Web of Science ®Google Scholar
• Chan WY, Entwisle C, Ercoli G, et al. A novel, multiple-antigen pneumococcal vaccine protects against lethal Streptococcus pneumoniae challenge. Infect Immun. 2019;87(3):e00846–18.
   PubMed Web of Science ®Google Scholar
• Lagousi T, Basdeki P, Routsias J, et al. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines (Basel). 2019;7(1):E9.
   PubMed Web of Science ®Google Scholar
• Perciani CT, Barazzone GC, Goulart C, et al. Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response. Clin Vaccine Immunol. 2013;20(6):858–866.
   PubMed Web of Science ®Google Scholar
• Da Silva MA, Converso TR, Gonçalves VM, et al. Conjugation of PspA4Pro with capsular Streptococcus pneumoniae polysaccharide serotype 14 does not reduce the induction of cross-reactive antibodies. Clin Vaccine Immunol. 2017;24(8):e00118–17.
   PubMed Web of Science ®Google Scholar
• Odutola A, Ota MOC, Antonio M, et al. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants. Vaccine. 2019;37(19):2586–2599.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, van Gils EJM, Veenhoven RH, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011;17:584–591.
   PubMed Web of Science ®Google Scholar
• Bosch AATM, van Houten MA, Bruin JP, et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2016;34:531–539.
   PubMed Web of Science ®Google Scholar
• Camilli R, Vescio MF, Giufrè M, et al. Carriage of Haemophilus influenzae is associated with pneumococcal vaccination in Italian children. Vaccine. 2015;33:4559–4564.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, Prevaes SMPJ, van Gils EJM, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One. 2012;7:e39730.
   PubMed Web of Science ®Google Scholar
• Biesbroek G, Wang X, Keijser BJF, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis. 2014;20:201–210.
   PubMed Web of Science ®Google Scholar
• Wiertsema SP, Kirkham L-AS, Corscadden KJ, et al. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3 + 0 pneumococcal conjugate vaccine schedule. Vaccine. 2011;29:5163–5170.
   PubMed Web of Science ®Google Scholar
• Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009;29:1.
   Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–409.
   PubMed Web of Science ®Google Scholar
• Nzenze SA, Shiri T, Nunes MC, et al. Temporal association of infant immunisation with pneumococcal conjugate vaccine on the ecology of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonisation in a rural South African community. Vaccine. 2014;32:5520–5530.
   PubMed Web of Science ®Google Scholar
• Lee GM, Huang SS, Rifas-Shiman SL, et al. Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis. 2009;9:110.
   PubMed Web of Science ®Google Scholar
• Navne JE, Koch A, Slotved H-C, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage by respiratory pathogens among Greenlandic children. Int J Circumpolar Health. 2017;76:1309504.
   PubMed Web of Science ®Google Scholar
• WHO 2016. [cited 2019 Apr 20] https://www.who.int/news-room/fact-sheets/detail/pneumonia
   Google Scholar
• Feikin DR, Hammitt LL, Murdoch DR, et al. The enduring challenge of determining pneumonia etiology in children: considerations for future research priorities. Clin Infect Dis. 2017;64(suppl_3):S188–S196.
   PubMedGoogle Scholar
• McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571–582.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavia N, Ben-Shimol S, et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33:4623–4629.
   PubMed Web of Science ®Google Scholar
• Alicino C, Paganino C, Orsi A, et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine. 2017;35:5776–5785.
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Hill PC, Sahito SM, et al. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies. Lancet Infect Dis. 2017;17:965–973.
   PubMed Web of Science ®Google Scholar
• Ouldali N, Levy C, Minodier P, et al. Long-term association of 13-valent pneumococcal conjugate vaccine implementation with rates of community-acquired pneumonia in children. JAMA Pediatr. 2019;173(4):362–370.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48–58.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000422. doi: 10.1002/14651858.CD000422.pub3. Review. PubMed PMID: 23440780.
   Google Scholar
• Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34:1496–1503.
   PubMed Web of Science ®Google Scholar
• Schiffner-Rohe J, Witt A, Hemmerling J, et al. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - a systematic review and meta-analysis. PLoS One. 2016;11(1):e0146338.
   PubMed Web of Science ®Google Scholar
• Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):e0177985.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Jiang Q, Scott DA, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018;36(11):1477–1483.
   PubMed Web of Science ®Google Scholar
• Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2018;31:S0264-410X(18)30763–1.
   Google Scholar
• Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015;33(Suppl.4):D60–D65.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–1506.
   PubMed Web of Science ®Google Scholar
• Prato R, Fortunato F, Cappelli MG, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case–control study in a 2-year prospective cohort. BMJ Open. 2018;8:e019034.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, de Diego C, et al. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. BMC Infect Dis. 2018;18:196.
   PubMed Web of Science ®Google Scholar
• España PP, Uranga A, Ruiz LA, et al. Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001–2014, after introduction of the pneumococcal conjugate vaccine in Bizkaia (Spain). Vaccine. 2019;37:3840–3848.
   PubMed Web of Science ®Google Scholar
• Jose RJ, Brown JS. Adult pneumococcal vaccination: advances, impact, and unmet needs. Curr Opin Pulm Med. 2017;23:225–230.
   PubMed Web of Science ®Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005;57(3):411–430.
   PubMed Web of Science ®Google Scholar
• Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res. 2013;3(1):100–109.
   PubMed Web of Science ®Google Scholar
• Garg NK, Mangal S, Khambete H, et al. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul. 2010;4(2):114–128.
   PubMedGoogle Scholar
• Carroll EC, Jin L, Mori A, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44(3):597–608.
   PubMed Web of Science ®Google Scholar
• Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15(4):5852–5873.
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu H, Zhang X, et al. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 2015;6(7):480–503.
   PubMed Web of Science ®Google Scholar
• Wright AKA, Bangert M, Gritzfeld JF, et al. Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog. 2013;9:e1003274.
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med. 2013;187:855–864.
   PubMed Web of Science ®Google Scholar
• Jambo KC, Sepako E, Heyderman RS, et al. Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol. 2010;18:81–89.
   PubMed Web of Science ®Google Scholar
• Perez E, Bonilla FA, Orange JS, et al. Specific antibody deficiency: controversies in diagnosis and management. Front Immunol. 2017;8:586.
   PubMed Web of Science ®Google Scholar
• Jambo KC, Sepako E, Fullerton DG, et al. Bronchoalveolar CD4+ T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax. 2011;66:375–382.
   PubMed Web of Science ®Google Scholar
• Nakada T, Russell JA, Boyd JH, et al. IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis. Crit Care. 2011;15:R254.
   PubMed Web of Science ®Google Scholar
• Gritzfeld JF, Wright AD, Collins AM, et al. Experimental human pneumococcal carriage. J Vis Exp. 2013;72:50115.
   Google Scholar
• Wright AKA, Ferreira DM, Gritzfeld JF, et al. Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog. 2012;8:e1002622. Wessels MR, editor. . Public Library of Science.
   PubMed Web of Science ®Google Scholar
• Mitsi E, Carniel C, Jochems SP, et al. Cross-talk of alveolar macrophages and T-cells boosts the lung immunity post nasopharyngeal pneumococcal colonisation. Presented at: 11th International Symposium on Pneumococci and Pneumococcal Diseases. Melbourne, Australia, 15–19 April 2018. Available: https://web.kenes.com/klead/ISPPD18AbstractCD/ISPPD2018/data/HtmlApp/main.html#18
   Google Scholar
• Wu H, Nahm MH, Guo Y, et al. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis. 1997;175:839–846.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Briles DE, Yamamoto S, et al. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol. 1998;161:4115–4121.
   PubMed Web of Science ®Google Scholar
• Miyaji EN, Oliveira MLS, Carvalho E, et al. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70:3303–3326.
   PubMed Web of Science ®Google Scholar
• Rodrigues TC, Oliveira MLS, Soares-Schanoski A, et al. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS One. 2018;13:e0191692.
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Darrieux M, Silva DA, et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol. 2009;16:636–645.
   PubMed Web of Science ®Google Scholar
• Yu J, Li B, Chen X, et al. Comparison of immunogenicity and protection of two pneumococcal protein vaccines based on PsaA and PspA. Infect Immun. 2018;86:e00916–17.
   PubMed Web of Science ®Google Scholar
• Nayak AR, Tinge SA, Tart RC, et al. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun. 1998;66:3744–3751.
   PubMed Web of Science ®Google Scholar
• Seo SU, Kim JJ, Yang H, et al. Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice. Vaccine. 2012;30:6816–6823.
   PubMed Web of Science ®Google Scholar
• Frey SE, Lottenbach KR, Hill H, et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine. 2013;31:4874–4880.
   PubMed Web of Science ®Google Scholar
• Muralinath M, Kuehn MJ, Roland KL, et al. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun. 2011;79:887–894.
   PubMed Web of Science ®Google Scholar
• Kuipers K, Daleke-Schermerhorn MH, Jong WS, et al. Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. Vaccine. 2015;33:2022–2029.
   PubMed Web of Science ®Google Scholar
• Oliveira ML, Areas AP, Campos IB, et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes infect/Inst. Pasteur. 2006;8:1016–1024.
   PubMed Web of Science ®Google Scholar
• Hanniffy SB, Carter AT, Hitchin E, et al. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis. 2007;195:185–193.
   PubMed Web of Science ®Google Scholar
• Campos IB, Darrieux M, Ferreira DM, et al. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes infect/Institut Pasteur. 2008;10:481–488.
   PubMed Web of Science ®Google Scholar
• Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol. 2013;4:282.
   PubMed Web of Science ®Google Scholar
• Lu J, Guo J, Wang D, et al. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments. Hum Vaccin Immunother. 2019;15(2):371–380.
   PubMed Web of Science ®Google Scholar
• Li B, Chen X, Yu J, et al. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice. Microb Pathog. 2018;123:115–119.
   PubMed Web of Science ®Google Scholar
• Kye Y-C, Park S-M, Shim B-S, et al. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection. Acta Biomater. 2019. DOI:10.1016/J.ACTBIO.2019.03.049.
   PubMed Web of Science ®Google Scholar
• Kunda NK, Alfagih IM, Miyaji EN, et al. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles. Int J Pharm. 2015;495(2):903–912.
   PubMedGoogle Scholar
• Xu J, Dai W, Wang Z, et al. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin vaccine Immunol. CVI. 2011;18(1):75–81.
   PubMed Web of Science ®Google Scholar
• Ai W, Yue Y, Xiong S, et al. Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell responses. Microbiol Immunol. 2013;57(3):224–235.
   PubMed Web of Science ®Google Scholar
• Xu JH, Dai WJ, Chen B, et al. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae. Scand J Immunol. 2015;81:177–185.
   PubMed Web of Science ®Google Scholar
• Kong IG, Sato A, Yuki Y, et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun. 2013;81:1625–1634.
   PubMed Web of Science ®Google Scholar
• Fukuyama Y, Yuki Y, Katakai Y, et al. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques. Mucosal Immunol. 2015;8:1144.
   PubMed Web of Science ®Google Scholar
• Trolle S, Chachaty E, Kassis-Chikhani N, et al. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumoniae. Vaccine. 2000;18:2991–2998.
   PubMed Web of Science ®Google Scholar
• Malley RM, Lipsitch A, Stack R, et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun. 2001;69:4870–4873.
   PubMed Web of Science ®Google Scholar
• Malley R, Srivastava A, Lipsitch M, et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun. 2006;74:2187–2195.
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Saeland E, Gizurarson S, et al. Intranasal with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun. 1999;67:4128–4133.
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Schulz D, Pizza M, et al. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun. 1999;67:5892–5897.
   PubMed Web of Science ®Google Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun. 2003;71:4780–4788.
   PubMed Web of Science ®Google Scholar
• Menzel M, Muellinger B, Weber N, et al. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine. 2005;23:5113–5119.
   PubMed Web of Science ®Google Scholar
• Meyer P, Menzel M, Muellinger B, et al. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine. 2006;24:5832–5838.
   PubMed Web of Science ®Google Scholar
• Gordon SB, Malamba R, Mthunthama N, et al. Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine. 2008;26:5400–5406.
   PubMed Web of Science ®Google Scholar